Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aegerion Pharma Inc (AEGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 55,250
  • Shares Outstanding, K 29,540
  • Annual Sales, $ 239,890 K
  • Annual Income, $ -73,340 K
  • 36-Month Beta 0.50
  • Price/Sales 0.23
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.07
  • Most Recent Earnings -0.37 on 11/03/16
  • Next Earnings Date 11/14/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +31.33%
on 11/07/16
2.34 -15.81%
on 11/29/16
+0.14 (+7.65%)
since 10/28/16
3-Month
1.50 +31.33%
on 11/07/16
3.35 -41.19%
on 09/29/16
+0.33 (+20.12%)
since 08/29/16
52-Week
1.23 +60.16%
on 06/14/16
10.85 -81.84%
on 12/24/15
-8.49 (-81.17%)
since 11/27/15

Most Recent Stories

More News
Corporate News Blog - Novelion's Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 Million

LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novelion Therapeutics Inc. (NASDAQ: NVLN) ("Novelion"), following...

AEGR : 1.97 (+5.35%)
NVLN : 6.72 (-0.15%)
Criminal and civil actions filed against Aegerion Pharmaceuticals Inc.

Today, Aegerion Pharmaceuticals Inc. agreed to plead guilty in the United States District Court for the District of Massachusetts to two misdemeanor counts of violating the Federal Food, Drug, and Cosmetic...

AEGR : 1.97 (+5.35%)
Pharmaceutical Company Paying Penalty for Misleading Investors About Sales Metric

The Securities and Exchange Commission today filed fraud charges against a Massachusetts-based biopharmaceutical company that exaggerated how many new patients actually filled prescriptions for an expensive...

AEGR : 1.97 (+5.35%)
NVLN : 6.72 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is...

See More

Support & Resistance

2nd Resistance Point 2.54
1st Resistance Point 2.25
Last Price 1.97
1st Support Level 1.77
2nd Support Level 1.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart